 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 3567-------------------------------------------------- |
|
(JAMA) 3rd dose of mRNA COVID-19 vaccine in MS patients treated |
|
with ocrelizumab |
|
By: agate Date: February 26, 2022, 1:39 am |
|
--------------------------------------------------------- |
|
From JAMA Neurology (February 22, 2022)--"Omicron-specific |
|
cytotoxic T-cell responses after a third dose of mRNA COVID-19 |
|
vaccine among patients with multiple sclerosis treated with |
|
ocrelizumab": |
|
https://bit.ly/3JWTnc3 |
|
***************************************************** |
